Interaction of a blood coagulation factor on electrically polarized hydroxyapatite surfaces
Source abstract
Abstract
Abstract Although the polarization treatment of hydroxyapatite (HA) remarkably enhances the osteoconductivity, the mechanisms have not yet been completely understood. The interaction of proteins in blood and tissue fluids with biomaterials are reportedly triggers for later cellular responses and played a major role in osteoconductive processes. Considering this, we disclosed the interaction of polarized HA surface with a coagulation factor, fibrin stabilizing factor XIII (FXIII). The HA activated FXIII even in Ca2+ free buffer, based on the SDS‐PAGE detections of α‐polymer and γ‐dimer bands assigned to stabilized fibrin. The Ca2+ ions, possibly released from the HA surfaces, were examined whether they initiate the activation of the FXIII. It was experimentally proved by ICP analysis that the induced large negative charges on the electrically polarized HA significantly increased the released Ca2+ concentration for the short pre‐incubation time of 3 min. The more Ca2+ ions released from the negatively charged HA (N‐HA) surfaces were more effective in the activation of the FXIII, resulting in the rapider disappearance of the γ‐chain bands in fibrin. The slightly lower Ca2+ concentration in the positively charged HA, compared to the nonpolarized HA activated the FXIII at an almost equal rate. The accelerated activation contributed to the stabilization of fibrin scaffold. Therefore, the polarity difference of the induced charges of the polarized HA surface altered the rate of the FXIII activation. The early stage interaction of the HA surfaces with blood proteins was considered to be an essential process of the accelerated new bone formation near implanted N‐HA surface. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2006
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Polymer Surface Interaction Studies · Periodontal Regeneration and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. 10.1021/cm960285810.1021/cm9602858 ↗
2. 10.2109/jcersj.113.110.2109/jcersj.113.1 ↗
3. 10.1002/1097-4636(20011215)57:4<477::AID-JBM1193>3.0.CO;2-510.1002/1097-4636(20011215)57:4<477::AID-JBM1193>3.0.CO;2-5 ↗
4. 10.1002/jbm.a.1012410.1002/jbm.a.10124 ↗
5. 10.1007/s00223-005-0213-610.1007/s00223-005-0213-6 ↗
6. 10.1016/S0142-9612(99)00160-X10.1016/S0142-9612(99)00160-X ↗
7. 10.1002/jcb.24056031010.1002/jcb.240560310 ↗
8. 10.1002/jbm.82020050910.1002/jbm.820200509 ↗
9. 10.1002/jbm.82023070410.1002/jbm.820230704 ↗
10. 10.1016/0142-9612(86)90032-310.1016/0142-9612(86)90032-3 ↗
11. 10.1016/0142-9612(89)90017-310.1016/0142-9612(89)90017-3 ↗
12. 10.1002/jbm.82018091710.1002/jbm.820180917 ↗
13. 10.2106/00004623-198264040-0001310.2106/00004623-198264040-00013 ↗
14. 10.1002/jbm.82025100910.1002/jbm.820251009 ↗
15. 10.1172/JCI11132610.1172/JCI111326 ↗
16. Surface thrombogenicity of arterial prostheses
17. 10.1016/0142-9612(87)90116-510.1016/0142-9612(87)90116-5 ↗
18. 10.1002/jbm.82021031010.1002/jbm.820210310 ↗
19. Nylon fiber leukapheresis: Associated complement component changes and cranulocytopenia10.1182/blood.V51.2.359.359 ↗
20. 10.1002/jbm.82020040910.1002/jbm.820200409 ↗
21. The role of blood coagulation components as intermediators of high osteoconductivity of electrically polarized hydroxyapatite
22. Human factor XIII rom plasma and platelets10.1016/S0021-9258(19)44312-3 ↗
23. 10.1016/S0065-3233(08)60217-X10.1016/S0065-3233(08)60217-X ↗
24. Isolation and characterization of the polypeptide chain involved in the cross‐linking of stabilized bovine fibrin10.1093/oxfordjournals.jbchem.a129519 ↗
25. 10.1007/BF0039372010.1007/BF00393720 ↗
26. 10.1007/BF0043564810.1007/BF00435648 ↗
27. 10.1021/bi00239a01410.1021/bi00239a014 ↗
28. 10.1002/jbm.1022410.1002/jbm.10224 ↗
29. 10.1063/1.135778310.1063/1.1357783 ↗
30. A γ Gly‐268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I10.1182/blood.V87.11.4686.bloodjournal87114686 ↗
31. 10.1111/j.1749-6632.2001.tb03516.x10.1111/j.1749-6632.2001.tb03516.x ↗
32. 10.1021/bi00701a01810.1021/bi00701a018 ↗
33. On the activation of bovine plasma factor XIII‐amino acid sequence of the peptide released by thrombin and the terminal residues of the subunit polypeptides
34. 10.1073/pnas.77.9.506910.1073/pnas.77.9.5069 ↗
35. 10.1021/bi00715a02410.1021/bi00715a024 ↗
36. 10.1002/jbm.82027010510.1002/jbm.820270105 ↗
37. 10.1016/S0142-9612(01)00180-610.1016/S0142-9612(01)00180-6 ↗
38. Hench LL · 1993 · 15910.1142/2028 ↗
39. 10.1111/j.1749-6632.1986.tb34577.x10.1111/j.1749-6632.1986.tb34577.x ↗
40. 10.1111/j.1749-6632.1986.tb34575.x10.1111/j.1749-6632.1986.tb34575.x ↗
41. 10.1002/jbm.a.1057710.1002/jbm.a.10577 ↗
42. 10.1002/(SICI)1097-4652(199801)174:1<58::AID-JCP7>3.0.CO;2-F10.1002/(SICI)1097-4652(199801)174:1<58::AID-JCP7>3.0.CO;2-F ↗
43. 10.1016/j.biomaterials.2004.06.01510.1016/j.biomaterials.2004.06.015 ↗
44. 10.1182/blood.V98.4.123110.1182/blood.V98.4.1231 ↗
45. 10.1016/S0142-9612(02)00618-X10.1016/S0142-9612(02)00618-X ↗
46. Is platelet‐rich plasma the perfect enhancement factor? A current review
47. 10.1097/00001665-200305000-0000610.1097/00001665-200305000-00006 ↗
48. Factor XIII cross‐linking of fibronectin at cellular matrix assembly sites10.1016/S0021-9258(19)81539-9 ↗
49. Cross‐linking of cold‐insoluble globulin by fibrin‐stabilizing factor10.1016/S0021-9258(19)41110-1 ↗
50. Fibronectin and fibrin gel structure10.1016/S0021-9258(18)89665-X ↗